Vivesto AB (OSTO:VIVE) Stock Based Compensation: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:VIVE Vivesto AB OSTO:VIVE
26 GF Score
Price kr8.30
! 1 Warning Sign
View Full Analysis

What is Vivesto AB Stock Based Compensation?

Vivesto AB OSTO:VIVE -4.82% 26 Stock Based Compensation is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:VIVE with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Vivesto AB's Stock Based Compensation for the three months ended in Mar. 2026 was kr0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Vivesto AB Stock Based Compensation Related Terms

Vivesto AB Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Vivesto AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB Stock Based Compensation Chart

Vivesto AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vivesto AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:VIVE
26GF Score
Vivesto AB OSTO:VIVE
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivesto AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

What does a Stock Based Compensation of kr0.00 Mil mean?
Vivesto AB (OSTO:VIVE) has a Stock Based Compensation of kr0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vivesto AB and its competitors.
Is Vivesto AB's Stock Based Compensation too high?
Vivesto AB's current Stock Based Compensation is kr0.00 Mil. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Stock Based Compensation compare to ZTS and UTHR?
Vivesto AB's Stock Based Compensation of kr0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vivesto AB and its competitors. Vivesto AB's current Stock Based Compensation is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OSTO:VIVE) has a current Stock Based Compensation of kr0.00 Mil. The current Stock Based Compensation is kr0.00 Mil. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Vivesto AB (OSTO:VIVE), the current Stock Based Compensation is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges OMA:Germany
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score

Get the complete analysis for OSTO:VIVE

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.30
Price